ISN Webinar: Unraveling the biology of GLP1-receptor agonist for obesity management and metabolic control in CKD

The rising prevalence of obesity among patients with chronic kidney disease (CKD) presents unique challenges in their management. This webinar, titled “Targeting Obesity in CKD Patients: The Role of Incretin Hormones and their Therapeutic Targets” aims to provide a comprehensive review of the biology and pharmacology of GLP1RA and the latest landscape of GLP1RA for obesity management in the CKD population. The webinar will discuss differences among the different GLP1RA and other incretin hormones, such as GIP, in body weight management and in metabolic control in CKD patients. Through an in-depth review of current research findings and clinical practice guidelines, this session will highlight the mechanisms, efficacy and potential risks of this new class of therapy and differences among the various GLP1-RA and discuss how this novel therapy may integrate with lifestyle intervention in practical management of obesity in CKD, with an aim to enhance patient outcomes and quality of life. 

Learning objectives:

- Review the biology and pharmacology of GLP1RA.
- Describe the latest landscape of incretin hormones, such as GLP-1RA and GIP, in obesityand metabolic management among chronic kidney disease (CKD) patients.
- Understand the latest evidence supporting the use of GLP-1 receptor agonists and other incretin-based therapies for weight management and metabolic control in CKD patientsand review differences in efficacies among the different GLP1RA and GIPs.
- Discuss potential risks associated with incretin-based therapies for obesity management in CKD.
- Future drug development for obesity management and relevance for CKD.

This webinar is supported by Novo Nordisk.